Jun 09, 2022 / 08:30PM GMT
Christopher Lawrence Howerton - Jefferies LLC, Research Division - Equity Analyst
Okay. Good afternoon, everybody. Thank you so much for joining us. My name is Chris Howerton, part of the biotechnology research team here at Jefferies. Really excited to be hosting a fireside chat with one of the most exciting companies I cover, Apellis. So on behalf of the management team, we have both the CFO, Tim Sullivan; and Adam Townsend, the Chief Commercial Officer. So thanks for joining us.
Timothy E. Sullivan - Apellis Pharmaceuticals, Inc. - CFO & Treasurer
Thank you for having us.
Adam J. Townsend - Apellis Pharmaceuticals, Inc. - Chief Commercial Officer
Thank you.
Questions and Answers:
Christopher Lawrence Howerton - Jefferies LLC, Research Division - Equity AnalystAll right. So I think for me, the biggest opportunity might be for pegcetacoplan in geographic atrophy. So where are we at in terms of the clinical package? And what will be submitted to the FDA at this
Trustpilot
